# Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens

Source: https://onco.cc/trials/nct06419179/  
OnCo record `nct06419179` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab and olaparib in lung cancer, run by University of Cologne, now recruiting.

## Summary

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) is a phase 2, interventional study registered as NCT06419179 by University of Cologne, with a registry enrolment figure of 29 participants, started 2024-10-09 and due to reach its primary completion in 2026-09. Interventions recorded: Durvalumab; Olaparib. Conditions listed: Small Cell Lung Carcinoma. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "* Newly diagnosed, histologically documented advanced or metastatic small-cell lung cancer (UICC stage III which is not amenable to curative radiochemotherapy or stage IV)". Sites: Germany. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: GUIDANCE
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06419179
- Phase: 2
- Setting: A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
- Sponsor: University of Cologne
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT06419179: https://clinicaltrials.gov/study/NCT06419179

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06419179.json